Pharmaceutical

WuXi AppTec's Q1 2025 Financial report Market Trend Financial statements WuXi AppTec WuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
Gilead's Q1 2025 Financial report Financial statements Market Trend Gilead Gilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
AbbVie's Q1 2025 Financial report Financial statements AbbVie Market Trend AbbVie’s Q1 2025 report reveals soaring sales of Skyrizi and Rinvoq amid Humira’s decline. Explore how innovation, competition, and strategic shifts are reshaping AbbVie’s future in immunology and beyond.
PD-(L)1 Resistance Hope PD-1 Immunotherapy Oncology ADC Explore how LRRC15+ CAFs contribute to PD-1 resistance, the role of LRRC15 in tumor immunity, and emerging therapies targeting LRRC15 and PD-1 to improve cancer immunotherapy outcomes.
The Cost of Attacking the Pharmaceutical Industry Trump Market Trend FDA NIH Trump's policies during his second term have rocked the U.S. scientific community, slashing NIH funding, threatening pharmaceutical innovation, and reshaping the global research landscape amid rising concerns about America's future in science.
Roche's Q1 2025 Financial report Financial statements Market Trend Roche Roche Q1 2025 financial results show 6% revenue growth, driven by strong demand for innovative drugs and diagnostics. China leads international growth, while the company makes strategic investments in the US and global R&D.
Merck's Q1 2025 Financial report Financial statements Market Trend Merck Merck's Q1 2025 earnings show a 2% decline in revenue, with strong growth in KEYTRUDA and animal health products. The company faces short-term challenges but continues to drive innovation in its R&D pipeline.
Sanofi's Q1 2025 Financial report Sanofi Financial statements Market Trend Sanofi's Q1 2025 report shows a 9.7% sales growth, driven by Dupixent and innovative drugs. The company confirms full-year guidance with strong performance in immunology, rare diseases, and vaccines.
BMS's Q1 2025 Financial report Market Trend Financial statements BMS Bristol Myers Squibb Bristol Myers Squibb Q1 2025 earnings: revenue down 6% YoY, but strong product performance drives EPS growth. Full-year guidance raised. Highlights include Opdivo, Reblozyl, and Breyanzi.
Major Breakthrough! These Targets Entered Clinical Trials for the First Time in 2025 Biopharmaceutical ACK1 CD83 Discover the groundbreaking entry of ACK1 and CD83 into clinical trials in 2025. Explore their potential in treating CRPC and AML, and how these novel targets may reshape the future of cancer therapy and pharmaceutical innovation.

< Pre 1...53 54 555657 58 59...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles